Mantle Cell Lymphoma Clinical Trials

A listing of Mantle Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 148 clinical trials
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.

  • 0 views
  • 27 Mar, 2021
  • 12 locations
Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma

This study evaluates adherence to a ketogenic diet in patients with low tumor burden, treatment-nave mantle cell lymphoma.

neutrophil count
platelet count
mantle cell lymphoma
  • 0 views
  • 01 Aug, 2021
  • 1 location
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects who have not received prior cytotoxic chemotherapy for their MCL (i.e., prior single agent …

hormone therapy
monoclonal antibodies
measurable disease
neutrophil count
platelet count
  • 82 views
  • 14 Apr, 2021
  • 1 location
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Patients with mantle cell lymphoma (MCL) that has relapsed (come back) or refractory (progressed on treatment) will receive ixazomib and ibrutinib. Ibrutinib has been approved by the Food

tyrosine
neutrophil count
measurable disease
hepatitis b surface antigen
refractory mantle cell lymphoma
  • 129 views
  • 01 Aug, 2021
  • 16 locations
Bendamustine Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

This phase II trial studies how well bendamustine, obinutuzumab, and venetoclax work in treating patients with mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and

venetoclax
monoclonal antibodies
neutrophil count
tumor cells
platelet count
  • 4 views
  • 16 May, 2021
  • 3 locations
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.

ibrutinib
neutrophil count
measurable disease
growth factor
hodgkin's disease
  • 22 views
  • 15 May, 2021
  • 7 locations
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Induction chemotherapy 1) RCHOP(Rituximab+Cyclophosphamide+Doxorubicin+Vincristine+Prednisone) 2) VR-CAP (Bortezomib+Rituximab+Cyclophosphamide+Doxorubicin+Prednisone) Patients who have received induction chemotherapy will be evaluated for responses and those who achieved more than PR(Partial response) or PR will be eligible for this study after receiving informed consents. 2. Experimental step Maintenance ixazomib beginning at least 8 weeks after completion …

prednisone
measurable disease
neutrophil count
cyclin d1
rituximab
  • 2 views
  • 25 Jan, 2021
  • 1 location
First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma

) and mantle cell lymphoma (MCL). NVG-111 is a bispecific antibody drug, having two "arms", one arm attaches to a substance on cancer cells called ROR1, the other arm attaches to the body's immune cells

venetoclax
monoclonal protein
tyrosine
lymphocytic leukemia
gilbert's syndrome
  • 0 views
  • 02 Jul, 2021
  • 1 location
Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma MCL MATCH Trial

This clinical trial collects and tests samples using genetic testing to find personalized treatments that may work best for patients with mantle cell lymphoma (MCL) that has come back (relapsed

  • 0 views
  • 14 May, 2021
  • 1 location
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma

  • 0 views
  • 27 Jun, 2021
  • 1 location